Alan Watt
Company: NodThera Ltd.
Job title: President & Chief Scientific Officer
Seminars:
Preclinical & Clinical Evaluation of the Brain Penetrant NLRP3 Inhibitor, NT-0796 in Obesity & Cardiometabolic Disease 9:30 am
day: Conference Day One AM
Overcoming Species-Specific Limitations in Preclinical Models for Human Disease 9:01 am
day: Pre-Conference Day
day: Pre-Conference Workshop Day